Research Analysts Set Expectations for MMSI FY2025 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Analysts at Zacks Research cut their FY2025 EPS estimates for shares of Merit Medical Systems in a research report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $3.67 for the year, down from their previous forecast of $3.70. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share.

MMSI has been the topic of several other reports. Needham & Company LLC dropped their target price on shares of Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Wells Fargo & Company lowered their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Barrington Research lowered their price target on shares of Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Piper Sandler restated an “overweight” rating and issued a $116.00 price target (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Finally, Raymond James raised their price target on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus price target of $110.78.

Merit Medical Systems Trading Down 0.2 %

MMSI stock opened at $101.28 on Friday. The company has a market capitalization of $5.96 billion, a PE ratio of 49.65, a P/E/G ratio of 2.34 and a beta of 0.91. Merit Medical Systems has a 12 month low of $70.70 and a 12 month high of $111.45. The firm’s 50-day moving average is $103.82 and its 200 day moving average is $100.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82.

Hedge Funds Weigh In On Merit Medical Systems

Several institutional investors have recently made changes to their positions in the company. Peak Retirement Planning Inc. purchased a new position in shares of Merit Medical Systems during the 4th quarter valued at approximately $875,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Merit Medical Systems by 17.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,344 shares of the medical instruments supplier’s stock valued at $15,992,000 after purchasing an additional 24,528 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in shares of Merit Medical Systems during the 4th quarter valued at approximately $424,000. Virtus Investment Advisers Inc. increased its holdings in shares of Merit Medical Systems by 45.7% during the 4th quarter. Virtus Investment Advisers Inc. now owns 11,192 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,513 shares in the last quarter. Finally, Tidal Investments LLC increased its holdings in shares of Merit Medical Systems by 3,197.9% during the 4th quarter. Tidal Investments LLC now owns 342,912 shares of the medical instruments supplier’s stock valued at $33,166,000 after purchasing an additional 332,514 shares in the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 5,361 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $103.58, for a total transaction of $555,292.38. Following the completion of the transaction, the chief financial officer now directly owns 24,201 shares of the company’s stock, valued at approximately $2,506,739.58. This trade represents a 18.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Fred P. Lampropoulos sold 31,320 shares of Merit Medical Systems stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the transaction, the chief executive officer now directly owns 1,086,028 shares of the company’s stock, valued at approximately $112,794,868.08. This trade represents a 2.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,132 shares of company stock valued at $11,139,521. 3.70% of the stock is owned by insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.